V

Viridian Therapeutics
D

VRDN

30.390
USD
1.07
(3.65%)
قبل الجلسة
حجم التداول
1
الربح لكل سهم
-5
العائد الربحي
-
P/E
-10
حجم السوق
2,900,482,623
أصول ذات صلة المقالات

العنوان: Viridian Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly knownas VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).